Showing results (331-340 of 415) with videos related to
Sort By:
Pageof 42
The American Journal of Surgical Pathology|February 2, 2010
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphomaMatija Snuderl, Olga K Kolman, Yi-Bin Chen, et al.Blood Advances|April 11, 2019
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemiaBenjamin L Lampson, Haesook T Kim, Matthew S Davids, et al.Lancet (London, England)|June 19, 2022
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trialManali Kamdar, Scott R Solomon, Jon Arnason, et al.Hematological Oncology|January 19, 2021
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 studyMartin Hutchings, John Radford, Stephen M Ansell, et al.Transplantation and Cellular Therapy|November 14, 2025
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World SettingBradley D Hunter, Matthew Lunning, Mazyar Shadman, et al.Blood Advances|July 17, 2025
Novel Devimistat Results in Complete Remissions in Heavily Pre-Treated Burkitt Lymphoma in a phase II trialRaphael E Steiner, Liana Nikolaenko, Ranjit Nair, et al.American Journal of Hematology|October 23, 2024
Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosisLeon D Kaulen, Philipp Karschnia, Sofia Doubrovinskaia, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25B Fisher, S Anderson, A DeCillis, et al.Vaccine|May 8, 2019
Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and responseCarleigh B Krubiner, Ruth R Faden, Ruth A Karron, et al.American Journal of Hematology|January 23, 2016
De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohortLapo Alinari, Alejandro Gru, Carl Quinion, et al.Pageof 42